CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 601 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration February 7, 2024 Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... September 26, 2023 Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... April 11, 2019 EMA Recommends to Extend the Indications for Tislelizumab May 8, 2025 Load more HOT NEWS EMA Recommends Extension of Indications for Tislelizumab Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on... 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously...
